

# Madelon C Vonk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3480832/publications.pdf>

Version: 2024-02-01

155  
papers

10,388  
citations

101543

36  
h-index

33894

99  
g-index

160  
all docs

160  
docs citations

160  
times ranked

9306  
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical Therapy in Systemic Sclerosis: The Patient Perspective. <i>Arthritis Care and Research</i> , 2023, 75, 145-151.	3.4	2
2	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. <i>Rheumatology</i> , 2022, 61, 743-755.	1.9	5
3	Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1476-1486.	1.9	7
4	A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 81-89.	1.6	3
5	The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 845359.	2.4	5
6	Evaluation of Left Cardiac Chamber Function with Cardiac Magnetic Resonance and Association with Outcome in Patients with Systemic Sclerosis. <i>Rheumatology</i> , 2022, , .	1.9	3
7	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. <i>Rheumatology</i> , 2022, 62, 234-242.	1.9	13
8	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	1.9	20
9	Requirements for systemic sclerosis expert centres in the Netherlands: A Delphi consensus study. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 96-101.	1.7	1
10	Is there still a role for cyclophosphamide in the treatment of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 117-122.	1.7	6
11	Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. <i>Rheumatology</i> , 2021, 60, 2467-2471.	1.9	19
12	Pulmonary hypertension in connective tissue diseases, new evidence and challenges. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13453.	3.4	28
13	Intestinal hypomotility in systemic sclerosis: a histological study into the sequence of events. <i>Clinical Rheumatology</i> , 2021, 40, 981-990.	2.2	6
14	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 96-106.	10.7	118
15	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. <i>Rheumatology</i> , 2021, 60, 5601-5609.	1.9	10
16	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. <i>BMJ Open</i> , 2021, 11, e044483.	1.9	11
17	Natural variability in the disease course of SSc-ILD: implications for treatment. <i>European Respiratory Review</i> , 2021, 30, 200340.	7.1	18
18	Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests. <i>Autoimmunity</i> , 2021, 54, 148-155.	2.6	17

#	ARTICLE	IF	CITATIONS
19	POS0054â€¦THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS PATIENTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 232.2-233.	0.9	5
20	Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSIS-ON Trial. , 2021, , .		1
21	AB0441â€¦NAILFOLD CAPILLAROSCOPY AND CANDIDATE BIOMARKER LEVELS IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY HYPERTENSION; PROFILING OF NON-INVASIVE MARKERS, A COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1248.3-1249.	0.9	0
22	OPO266â€¦EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSIS TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 162.1-162.	0.9	5
23	Physical therapy in patients with systemic sclerosis: physical therapistsâ€™ perspectives on current delivery and educational needs. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-8.	1.1	2
24	Change of the microvascularization in systemic sclerosis, a matter of air. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101683.	3.3	9
25	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	3.3	22
26	Photoacoustic and high-frequency ultrasound imaging of systemic sclerosis patients. <i>Arthritis Research and Therapy</i> , 2021, 23, 22.	3.5	17
27	Opening the black box of non-pharmacological care in systemic sclerosis: a cross-sectional online survey of Dutch health professionals. <i>Rheumatology International</i> , 2021, 41, 1299-1310.	3.0	2
28	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. <i>Autoimmunity Reviews</i> , 2021, 20, 102978.	5.8	17
29	Fibroblast Activation Protein Targeted Photodynamic Therapy Selectively Kills Activated Skin Fibroblasts from Systemic Sclerosis Patients and Prevents Tissue Contraction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12681.	4.1	9
30	Living with systemic sclerosis: exploring its impact on caregivers. <i>Disability and Rehabilitation</i> , 2020, 42, 1632-1633.	1.8	3
31	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5â€‰%years from diagnosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 57-65.	1.7	8
32	How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?. <i>Rheumatology</i> , 2020, 59, 1226-1232.	1.9	11
33	Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1550-1555.	1.9	8
34	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	5.8	231
35	Treatment decision-making in diffuse cutaneous systemic sclerosis: a patientâ€™s perspective. <i>Rheumatology</i> , 2020, 59, 2052-2061.	1.9	13
36	Room for improvement in non-pharmacological systemic sclerosis care? â€” a cross-sectional online survey of 650 patients. <i>BMC Rheumatology</i> , 2020, 4, 43.	1.6	7

#	ARTICLE	IF	CITATIONS
37	From "being at war" to "getting back on your feet": A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 202-209.	1.7	2
38	Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, NP7-NP11.	1.7	2
39	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1084-1089.	0.9	32
40	TGF $\beta$ -mediated expression of TGF $\beta$ -activating integrins in SSc monocytes: disturbed activation of latent TGF $\beta$ ?. <i>Arthritis Research and Therapy</i> , 2020, 22, 42.	3.5	12
41	Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels. <i>Autoimmunity Reviews</i> , 2020, 19, 102515.	5.8	17
42	Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSICIS Trial by Corticosteroid Use*. <i>Pneumologie</i> , 2020, 74, .	0.1	0
43	AB0582...DIAGNOSING SYSTEMIC SCLEROSIS WITH PHOTOACOUSTIC AND HIGH-FREQUENCY ULTRASOUND IMAGING. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1588.1-1588.	0.9	1
44	SAT0313...CORRELATION BETWEEN PROGRESSION OF SKIN FIBROSIS AND PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH SSC-ILD: DATA FROM THE SENSICIS TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1101.2-1102.	0.9	0
45	E070...Shared decision-making in progressive diffuse cutaneous systemic sclerosis: a patient's perspective. <i>Rheumatology</i> , 2019, 58, .	1.9	3
46	Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". <i>Autoimmunity Reviews</i> , 2019, 18, 102394.	5.8	79
47	Chronic Q fever associated with systemic sclerosis. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13123.	3.4	7
48	Treatment of Diffuse Cutaneous Systemic Sclerosis with Biologics, Small Molecules and Stem Cell Transplantation: What Is the Evidence to Date?. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 104-114.	1.4	0
49	SAT0259...PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0
50	AB0650...PERSPECTIVES AND UNMET NEEDS OF PATIENTS WITH POOR PROGNOSIS SYSTEMIC SCLEROSIS ON AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION CARE: A QUALITATIVE STUDY. , 2019, , .		0
51	SAT0282...EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN DAILY CLINICAL PRACTICE, A CASE SERIES. , 2019, , .		0
52	OP0079...HPR NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: OPENING THE BLACK BOX. , 2019, , .		0
53	PARE0019...LIVING WITH SYSTEMIC SCLEROSIS: EXPLORING ITS IMPACT ON CAREGIVERS: A QUALITATIVE STUDY. , 2019, , .		0
54	Optimal care for systemic sclerosis patients: recommendations from a patient-centered and multidisciplinary mixed-method study and working conference. <i>Clinical Rheumatology</i> , 2019, 38, 1007-1015.	2.2	16

#	ARTICLE	IF	CITATIONS
55	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	5.6	41
56	High-frequency photoacoustic and ultrasound imaging of systemic sclerosis patients. , 2019, , .		1
57	Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis. <i>Journal of Rheumatology</i> , 2018, 45, 441.1-442.	2.0	5
58	Regarding "Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea". <i>Journal of Investigative Dermatology</i> , 2018, 138, 1212-1215.	0.7	11
59	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
60	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	1.9	53
61	P076...A bioassay to measure tgfi activity reveals decreased tgfi activity in systemic sclerosis serum. , 2018, , .		0
62	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 128-132.	0.9	20
63	There is a need for new systemic sclerosis subset criteria. A content analytic approach. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 62-70.	1.1	28
64	What moves the rheumatologist? Unravelling decision making in the referral of systemic sclerosis patients to health professionals: a qualitative study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky027.	0.7	6
65	Unraveling SSc Pathophysiology; The Myofibroblast. <i>Frontiers in Immunology</i> , 2018, 9, 2452.	4.8	103
66	Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function. <i>Clinical Rheumatology</i> , 2018, 37, 2715-2722.	2.2	15
67	Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. <i>Trials</i> , 2018, 19, 449.	1.6	14
68	A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol. <i>BMJ Open</i> , 2018, 8, e020479.	1.9	21
69	FRI0437...Is extended auto antibody profiling associated with the prevalence of disease complications?. , 2018, , .		0
70	THU0719-HPR...Non-pharmacological care in systemic sclerosis: room for improvement?. , 2018, , .		0
71	SAT0485...What is the effect of cyclophosphamide iv pulse therapy in patients with diffuse cutaneous systemic sclerosis on skin involvement: an observational study. , 2018, , .		0
72	AB0776...Muscle ultrasonography: a potential new diagnostic tool for inflammatory myopathies. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	THU0655â€¦Patientsâ€™ evaluation of dutch health care in systemic sclerosis: unmet needs and preferences. , 2018, , .		0
74	AB0053â€¦A bioassay to measure tgff <sup>1</sup> activity reveals decreased tgff <sup>1</sup> activity in ssc serum. , 2018, , .		0
75	AB0787â€¦The eular systemic sclerosis impact of disease (SCLEROID) score â€œ a new patient-reported outcome measure for patients with systemic sclerosis. , 2018, , .		0
76	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.9	107
77	Pulmonary arterial hypertension, a novelty in idiopathic inflammatory myopathies: insights and first experiences with vasoactive therapy. RMD Open, 2017, 3, e000331.	3.8	6
78	Muscle ultrasonography is a potential tool for detecting fasciitis in dermatomyositis and polymyositis: comment on the article by Yoshida etÂal. Arthritis and Rheumatology, 2017, 69, 2248-2249.	5.6	4
79	OP0034â€¦Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the detect cohort. , 2017, , .		0
80	An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. Journal of Rheumatology, 2017, 44, 1453-1457.	2.0	25
81	AB0669â€¦The eular systemic sclerosis impact of disease (SCLEROID) score â€œ a new patient-reported outcome measure for patients with systemic sclerosis â€œ preliminary results from the ongoing validation study. , 2017, , .		0
82	AB0003â€¦A mif promoter polymorphism is associated with the susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis patients. , 2017, , .		0
83	AB0651â€¦The effect of cyclophosphamide on pulmonary function and dependence on disease activity of interstitial lung disease associated with systemic sclerosis. , 2017, , .		0
84	AB0178â€¦Phenotyping of natural killer (NK) receptors on NK and NKT-LIKE cells discloses defective immune-regulatory capability in patients with systemic sclerosis. , 2017, , .		0
85	The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. Rheumatology, 2017, 56, 844-852.	1.9	13
86	056.â€¢CHARACTERISTICS BY AUTOANTIBODY STATUS IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: THE EUROPEAN SCLERODERMA OBSERVATIONAL STUDY COHORT. Rheumatology, 2017, 56, .	1.9	0
87	Pulmonary Hypertension in Systemic Sclerosis. , 2017, , .		0
88	OP0123â€¦Prediction of progressive skin thickening in early diffuse systemic sclerosis using three-monthly skin scores from the european scleroderma observational study (ESOS). , 2017, , .		0
89	THU0764-HPRâ€¦What moves the rheumatologist? unravelling decision making in ssc referral â€œ a qualitative study. , 2017, , .		0
90	Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 48-55.	0.8	2

#	ARTICLE	IF	CITATIONS
91	AB0650â€¦Survival and Organ Involvement in Patients with Limited Cutaneous Systemic Sclerosis and Anti-Topoisomerase Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1126.3-1127.	0.9	0
92	Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4?. <i>Rheumatology</i> , 2016, 55, 2066-2073.	1.9	28
93	Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. <i>Journal of Rheumatology</i> , 2016, 43, 1838-1843.	2.0	21
94	Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. <i>Rheumatology</i> , 2016, 55, 2001-2008.	1.9	34
95	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. <i>Rheumatology</i> , 2016, 55, 2023-2032.	1.9	9
96	FRI0261â€¦Observational Study of Outcome in Patients with Early Diffuse Cutaneous Systemic Sclerosis Treated with Immunosuppressive Therapies (ESOS Study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 528.2-529.	0.9	1
97	SAT0196â€¦Impress 2 (International Multicentric Prospective Study on Pregnancy in Systemic Sclerosis). Prospective, Case-Control Study of Pregnancy in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 739.1-739.	0.9	0
98	FRI0254â€¦The Effect of Cyclophosphamide on Lung Function in Different Stages of Interstitial Lung Disease Associated To Systemic Sclerosis: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 526.1-526.	0.9	0
99	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€¦Disease Metaâ€¦Analysis of Genomeâ€¦Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2338-2344.	5.6	46
100	The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1567-1573.	0.9	126
101	SAT0641-HPRâ€¦Three-Year Trajectories of Disability and Fatigue in Systemic Sclerosis: A Cohort Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1335.3-1335.	0.9	2
102	AB0727â€¦There is a Need for New Systemic Sclerosis Subset Criteria. A Content Analytic Approach. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1141.2-1141.	0.9	1
103	AB0217â€¦Plasma Levels of Candidate Soluble Biomarkers of Disease Activity in Early Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 964.1-964.	0.9	0
104	Increased fascial thickness of the deltoid muscle in dermatomyositis and polymyositis: An ultrasound study. <i>Muscle and Nerve</i> , 2015, 52, 534-539.	2.2	30
105	SAT0437â€¦Occurrence of Organ Involvement in Early Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 818.1-818.	0.9	0
106	Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan. <i>Rheumatology</i> , 2015, 54, 262-269.	1.9	16
107	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.8	4
108	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014, 16, 493.	3.5	44

#	ARTICLE	IF	CITATIONS
109	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	7.4	566
110	Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis. <i>New England Journal of Medicine</i> , 2014, 370, 433-443.	27.0	365
111	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. <i>Arthritis Research and Therapy</i> , 2014, 16, R6.	3.5	37
112	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1340-1349.	0.9	633
113	Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. <i>Arthritis Research and Therapy</i> , 2014, 16, R111.	3.5	45
114	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	5.0	52
115	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
116	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.9	1,705
117	New insight on the Xq28 association with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2032-2038.	0.9	52
118	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 602-607.	0.9	56
119	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1233-1238.	0.9	30
120	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. <i>Human Molecular Genetics</i> , 2013, 22, 4021-4029.	2.9	104
121	FRI0248...Effects of bosentan in a homogeneous population of SSC subjects with a predefined restriction of blood flow in the hands (home): Preliminary results. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 398.1-398.	0.9	0
122	THU0247...Home: The effect of systemic sclerosis on the blood flow in the hands. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 238.2-238.	0.9	0
123	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. <i>PLoS ONE</i> , 2013, 8, e54419.	2.5	38
124	The role of the NLRP1 gene in systemic sclerosis: a replication study. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 187-8.	0.8	0
125	Heme oxygenase-1 promoter polymorphisms do not influence susceptibility to systemic sclerosis and its clinical phenotypes. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 186.	0.8	0
126	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. <i>Human Molecular Genetics</i> , 2012, 21, 926-933.	2.9	74



#	ARTICLE	IF	CITATIONS
127	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. <i>Human Molecular Genetics</i> , 2012, 21, 2825-2835.	2.9	98
128	Influence of the <i>IL6</i> Gene in Susceptibility to Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 2294-2302.	2.0	34
129	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. <i>Journal of Rheumatology</i> , 2012, 39, 112-118.	2.0	8
130	Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. <i>Journal of Psychosomatic Research</i> , 2012, 72, 199-204.	2.6	54
131	<i>KCNA5</i> gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. <i>Arthritis Research and Therapy</i> , 2012, 14, R273.	3.5	10
132	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R154.	3.5	11
133	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	3.5	32
134	Validity of the Fear of Progression Questionnaire—Short Form in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 930-934.	3.4	34
135	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	3.4	49
136	Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial. <i>Blood</i> , 2012, 120, 964-964.	1.4	5
137	Platelet-derived growth factor receptor- $\beta$ and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study. <i>Arthritis Research and Therapy</i> , 2011, 13, R61.	3.5	41
138	A replication study confirms the association of <i>TNFSF4 (OX40L)</i> polymorphisms with systemic sclerosis in a large European cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 638-641.	0.9	63
139	Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 454-462.	0.9	75
140	Rituximab treatment in patients with refractory inflammatory myopathies. <i>Rheumatology</i> , 2011, 50, 2206-2213.	1.9	88
141	Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. <i>Rheumatology</i> , 2011, 50, 1976-1981.	1.9	27
142	The Functional Polymorphism 844 A>G in Fc $\gamma$ RI (CD89) Does Not Contribute to Systemic Sclerosis or Rheumatoid Arthritis Susceptibility. <i>Journal of Rheumatology</i> , 2011, 38, 446-449.	2.0	4
143	Association of a non-synonymous functional variant of the ITCAM gene with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2050-2052.	0.9	15
144	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	3.5	201

#	ARTICLE	IF	CITATIONS
145	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	21.4	351
146	Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2213-2216.	0.9	36
147	The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 696-699.	0.9	49
148	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	2.0	9
149	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.9	1,017
150	Exercise in systemic sclerosis intensifies systemic inflammation and oxidative stress. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 63-70.	1.1	14
151	Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S18-27.	0.8	45
152	The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. <i>Human Molecular Genetics</i> , 2009, 18, 2071-2077.	2.9	163
153	The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: Results from a multicenter study of European Caucasian patients. <i>Human Immunology</i> , 2009, 70, 130-133.	2.4	9
154	Social Support, Disease-Related Cognitions and Coping as Predictors of Depressed Mood in Systemic Sclerosis. <i>Cognitive Therapy and Research</i> , 2008, 32, 434-447.	1.9	7
155	What does the clinician need to improve patient care in systemic sclerosis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1129-1131.	0.9	2